CCL18 and interstitial lung disease: Using a threshold of 303.5 ng/mL, defined by the ROC curve, CCL18 showed an 82% sensitivity, 69% specificity, 67% PPV and 83% NPV in predicting the occurrence of PF-ILD in our cohort.